{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:23:20Z","timestamp":1784294600818,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.biologicals.2016.10.004","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T04:15:57Z","timestamp":1500524157000},"page":"76-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions"],"prefix":"10.1016","volume":"49","author":[{"given":"Deborah A.","family":"Grosenbaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Frances-Duvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Feilmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Poulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2016.10.004_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jfms.2008.03.002","article-title":"American Association of Feline Practitioners' feline retrovirus management guidelines","volume":"10","author":"Levy","year":"2008","journal-title":"J\u00a0Feline Med Surg"},{"key":"10.1016\/j.biologicals.2016.10.004_bib2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2460\/javma.1991.199.10.1287","article-title":"Feline leukemia virus infection and diseases","volume":"199","author":"Hoover","year":"1991","journal-title":"J\u00a0Am Vet Med Assoc"},{"key":"10.1016\/j.biologicals.2016.10.004_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1748-5827.1997.tb03339.x","article-title":"Feline leukaemia virus: a review of immunity and vaccination","volume":"38","author":"Sparkes","year":"1997","journal-title":"J\u00a0Small Anim Pract"},{"key":"10.1016\/j.biologicals.2016.10.004_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.vetimm.2009.10.017","article-title":"Feline leukemia virus immunity induced by whole inactivated virus vaccination","volume":"134","author":"Torres","year":"2010","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0264-410X(91)90262-5","article-title":"Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats","volume":"9","author":"Maraciani","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2016.10.004_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/vr.153.5.141","article-title":"Efficacy of a canarypox virus-vectored vaccine against feline leukaemia","volume":"153","author":"Poulet","year":"2003","journal-title":"Vet Rec"},{"key":"10.1016\/j.biologicals.2016.10.004_bib7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/1098612X13509995","article-title":"Seroprevalence of feline leukemia virus, feline immunodeficiency virus and heartworm infection among owned cats in tropical Mexico","volume":"16","author":"Ortega-Pacheco","year":"2014","journal-title":"J\u00a0Feline Med Surg"},{"key":"10.1016\/j.biologicals.2016.10.004_bib8","first-page":"849","article-title":"Feline leukemia virus and feline immunodeficiency virus in Canada: recommendations for testing and management","volume":"52","author":"Little","year":"2011","journal-title":"Can Vet J"},{"key":"10.1016\/j.biologicals.2016.10.004_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7589\/2012-08-206","article-title":"Risk factors for exposure to feline pathogens in California mountain lions (Puma concolor)","volume":"49","author":"Foley","year":"2013","journal-title":"J\u00a0Wildl Dis"},{"key":"10.1016\/j.biologicals.2016.10.004_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vetimm.2009.10.010","article-title":"Feline leukemia virus infection: a threat for the survival of the critically endangered Iberian lynx (Lynx pardinus)","volume":"134","author":"Meli","year":"2010","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1746-6148-8-125","article-title":"Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-relate resistance to infection","volume":"8","author":"Wilson","year":"2012","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.biologicals.2016.10.004_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1939-1676.1993.tb03166.x","article-title":"Immunogenicity and efficacy of a commercial feline leukemia virus vaccine","volume":"7","author":"Pedersen","year":"1993","journal-title":"J\u00a0Vet Intern Med"},{"key":"10.1016\/j.biologicals.2016.10.004_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2005.09.010","article-title":"Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays","volume":"24","author":"Hofmann-Lehmann","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2016.10.004_bib14","first-page":"258","article-title":"Comparison of the Safety and Efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered subcutaneously","volume":"5","author":"Grosenbaugh","year":"2004","journal-title":"Vet Ther"},{"key":"10.1016\/j.biologicals.2016.10.004_bib15","first-page":"5","article-title":"A\u00a0comparative study of the efficacy of a canarypox based recombinant leukemia vaccine against a natural contact FeLV challenge in cats","volume":"6","author":"Sparkes","year":"2015","journal-title":"J\u00a0Vaccine Vaccin"},{"key":"10.1016\/j.biologicals.2016.10.004_bib16","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/j.vaccine.2014.03.016","article-title":"Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge","volume":"32","author":"Stuke","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2016.10.004_bib17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1128\/CVI.00034-15","article-title":"Comparative efficacy of feline leukemia virus (FeLV) inactivated whole-virus vaccine and canarypox virus-vectored vaccice during virulent FeLV challenge and immunosuppression","volume":"22","author":"Patel","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib18","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2006.12.022","article-title":"Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up","volume":"25","author":"Hofmann-Lehmann","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2016.10.004_bib19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1128\/JVI.02234-13","article-title":"A\u00a0targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine","volume":"88","author":"Schlecht-Louf","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jviromet.2005.06.017","article-title":"Quantitation of feline leukaimia virus viral and proviral loads by TaqMan\u00ae real-time polymerase chain reaction","volume":"130","author":"Tandon","year":"2005","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.biologicals.2016.10.004_bib21","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1128\/JVI.67.4.2370-2375.1993","article-title":"Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL","volume":"67","author":"Tartaglia","year":"1993","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib22","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1016\/j.vaccine.2006.11.066","article-title":"Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform","volume":"25","author":"Poulet","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2016.10.004_bib23","first-page":"100","article-title":"Feline leukemia virus (FeLV)-specific IFN\u03b3+ T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine","volume":"4","author":"El Garch","year":"2006","journal-title":"Int J Appl Res Vet Med"},{"key":"10.1016\/j.biologicals.2016.10.004_bib24","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1128\/CVI.00497-15","article-title":"Immunosuppression in a comparative study of feline leukemia virus vaccines","volume":"22","author":"Poulet","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1321.009","article-title":"Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies","volume":"1024","author":"Franchimont","year":"2004","journal-title":"Ann N. Y Acad Sci"},{"key":"10.1016\/j.biologicals.2016.10.004_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-60327-040-3_6","article-title":"Absolute quantitation of feline leukemia virus proviral DNA and viral RNA loads by TaqMan real-time PCR and RT-PCR","volume":"249","author":"Cattori","year":"2008","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.biologicals.2016.10.004_bib27","series-title":"Abstract of 7th International feline retrovirus Research Symposium, Pisa, Italy","article-title":"Efficacy of Feline Immunodeficiency Virus vaccines FEL-O-VAX and FIVGL8\u0394IN DNA vaccine: effect of the route of challenge on the outcome","author":"Dunham","year":"2004"},{"key":"10.1016\/j.biologicals.2016.10.004_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2460\/javma.241.5.595","article-title":"Comparative vaccine-specific and other injectable-specific risks of injection-site sarcomas in cats","volume":"241","author":"Srivastav","year":"2012","journal-title":"J\u00a0Am Vet Med Assoc"},{"key":"10.1016\/j.biologicals.2016.10.004_bib29","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1016\/j.vaccine.2007.02.049","article-title":"A\u00a0kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines","volume":"25","author":"Day","year":"2007","journal-title":"Vaccine"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510561630121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510561630121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T17:05:51Z","timestamp":1719335151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104510561630121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":29,"alternative-id":["S104510561630121X"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2016.10.004","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}